CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 200 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05307549
NCT05307549N/ACompleted

COVID-19 and Brain: Cognition and Mental Health

University of Barcelona·observational·Posted Apr 1, 2022·Updated May 30, 2023

In Brief

An observational study for COVID-19. Completed, enrolled 200 participants across 1 site.

Detailed Summary

The main goal of DIANA is to investigate the potential discriminative power of multimodal biomarkers in COVID adverse outcomes. The study of the neuropathological underlying mechanisms in COVID from a translational approach at: (1) the behavioural-clinical level from cognitive, emotional and functional data; (2) the brain connectome level from structural and functional imaging data; and (3) biogenetic level from blood and stool data. Moreover, the investigators will develop machine learning based predictive models of cognitive, mental health, functionality, and brain connectivity evolution in post-COVID syndrome patients.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesSpain

Timeline

N/ACompletedFinished
20222023202420252026
First PostedApr 1, 2022
Enrollment StartMay 14, 2021
Primary CompletionNov 30, 2022
Study CompletionDec 31, 2022
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 4.3 years ago